Oppenheimer resumed coverage on Tarsus Pharmaceuticals with a new price target

6/2/25 8:55:36 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Oppenheimer resumed coverage of Tarsus Pharmaceuticals with a rating of Outperform and set a new price target of $75.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$TARS

Date	Price Target	Rating	Analyst
6/2/2025	$75.00	Outperform	Oppenheimer
5/27/2025	$72.00	Buy	H.C. Wainwright
11/20/2023	$19.00	Neutral	Goldman
7/18/2023	$44.00	Outperform	William Blair
5/18/2023		Buy	Guggenheim
8/1/2022	$40.00	Overweight	Barclays
12/21/2021	$40.00	Buy	HC Wainwright & Co.
11/23/2021	$55.00	Outperform	Oppenheimer